GLOBAL-LEADERS All-Cause Mortality Subgroup Calculator

GLOBAL-LEADERS All-Cause Mortality Subgroup Calculator: Explanation and Clinical Context The GLOBAL-LEADERS trial was an open‐label, all‐comers randomized study of 1 month of aspirin + ticagrelor followed by 23 months of ticagrelor monotherapy vs 12 months of DAPT followed by 12 months of aspirin in patients undergoing PCI with a biolimus‐eluting stent. The primary outcome (all-cause mortality or non-fatal myocardial infarction) did not reach statistical superiority. Several subgroup and post-hoc analyses (including all-cause mortality) have been reported, though a fully published risk prediction model for all-cause mortality has not been made publicly available.

This calculator uses a simplified logistic model to provide an illustrative estimated risk of 2-year all-cause mortality in a PCI population similar to GLOBAL-LEADERS participants. Clinicians should interpret the result cautiously and in the context of the individual patient.